Key Record Dates
| ClinicalTrials.gov Identifier: | NCT03835819 |
|---|---|
| Brief Title: | A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC) |
| First Submitted : | February 6, 2019 |
| First Submitted that Met QC Criteria : | February 7, 2019 |
| First Posted : | February 11, 2019 |
| Last Update Submitted that Met QC Criteria : | November 13, 2023 |
| Last Update Posted : | November 14, 2023 |